COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro-6

Ntrations of CXB, DMC, or UMC for up to 2 months in the same cell culture dishes (i.e., without splitting the cell monolayers). In A., cells were treated with or without 20 μM DMC and photomicrographs (400× magnification) were taken after 6 weeks. Note that in the presence of drug (lower panels) the individual cells are noticeably larger, and the overall monolayer consists of fewer cells per surface area. In B., cells were treated with increasing concentrations of CXB and the total number of cells per well (6-well plate) was determined after 4 weeks (shown is the average of two counts). In all instances, the phenotypic changes were similar in the case of CXB, UMC, or DMC (not shown for all treatment conditions), except that DMC was the most potent, and UMC the least potent, compound. These experiments were repeated with very similar outcomes.<p><b>Copyright information:</b></p><p>Taken from "COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro"</p><p>Molecular Cancer 2008;7():38-38.</p><p>Published online 16 May 2008</p><p>PMCID:PMC2396175.</p><p>